Markets

U.S. Department Of Health And Human Services Announces Availability Of Enforcement Discretion Policy Regarding 503a Compounding Using Certain Peptide Bulk Drug Substances; Will Not Enforce Against Pharmacies, Federal Facilities Or Physicians Compounding Drugs Using Peptide Bulk Substances Pending Rulemaking; Interim Policy Permits Peptide Compounding Pending Final Rulemaking On 503a Bulk Drug Substances List

Oct 28, 2026 · 11:31 AM ET· updated 3h ago

https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances

Why It Matters

The government said it will not punish pharmacies for making peptide drugs right now. This gives compounding businesses and telehealth companies like Hims more freedom to operate.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

SPY771.04

+1.38 (+0.18%)

HIMS29.21

+1.29 (+4.62%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.